The authors identified distinct acquired mutations which converges on the RB1/E2F axis and result in decoupling of EZH2-dependent differentiation and cell cycle control, allowing tumour cells to escape tazemetostat-induced G1 arrest. This evidence concerns the gene EZH2 and neoplasm.